National and international regulatory and legislative approach governing drug safety: confronting drug counterfeiting in developing countries

Document Type : Original Article

Authors

1 Department of International Law, Karaj Branch, Islamic Azad University, Karaj, Iran

2 Department of Private Law, Karaj Branch, Islamic Azad University, Karaj, Iran.

Abstract

In the ecosystem of the health system, ensuring quality control, safety and effectiveness of drugs is very sensitive and necessary for people's health. After the Covid-19 pandemic, fake vaccine drugs have been circulating and seriously threatening public health around the world. This situation needs to pay more attention to the quality and more effective safety of medicine with the aim of combating drug counterfeiting. The current measures are not effective and sufficient to deal with all the problems associated with counterfeit drugs. In this article, by examining the importance of drug safety monitoring, it was observed that developing countries do not have adequate, standardized and integrated international monitoring regulations to evaluate the quality and safety of drugs. Finally, due to the lack of control over the supply chain, drugs will easily enter the flow of forgery and fraud. The existence of strong monitoring institutions in accordance with the standards of national or international laws, as well as the application of deterrent punishments in each of the stages of the drug production, distribution and delivery cycle, is required. This research is based on an analytical-descriptive method and on the basis of authentic library documents and sources. The theoretical framework of the research is rights based on justice.

Keywords

Main Subjects

References

  1. References

    Book

    1. World Health Organization, Health legislation at the dawn of the 21st century, Manual published by the World Health Organization, Volume 49, Number 1, 1998.

    Articles

    1. Acuna-Johnson, Patricia. “Drug safety in Chile”, In: Drug Safety in Developing Countries, Academic Press, 2020.
    2. Al-Worafi, Yaser Mohammed. “Drug safety in United Arab Emirates”, In: Drug safety in developing countries, Academic Press, 2020.
    3. Al-Worafi, Yaser Mohammed., Wafa Mohammed, Alseragi., Long Chiau, Ming and Khalid, M. Alakhali. “Drug safety in China”, In: Drug safety in developing countries, Academic Press, 2020.
    4. Atif, Muhammad., Iram, Malik., Muhammad, Asif., Muhammad, Qamar-Uz-Zaman., Nafees, Ahmad and Shane, Scahill. “Drug safety in Pakistan”, In: Drug safety in developing countries, Academic Press, 2020.
    5. Attaran, Amir. Roger Bate and Megan Kendall. “Why and how to make an international crime of medicine counterfeiting”, Journal of International Criminal Justice, 9 (2), 2011.
    6. Bate, Roger and Kimberly, Hess. “Assessing website pharmacy drug quality: safer than you think?”, PloS one,5 (8), 2010.
    7. Beyranvandi, Nematollah and Qabad Kazemi, “Victims of Medication trafficking”, Journal of studies in Islamic law and Jurisprudence, 14 (29), 2022. (in Persian)
    8. Davis, Karen, D., Nima, Aghaeepour., Andrew, H. Ahn., Martin, S. Angst., David, Borsook., Ashley, Brenton., Michael, E. Burczynski., et al. “Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities”, Nature Reviews Neurology, Volume 16, Issue 7, 2020.
    9. Elsayed, Tarek and Yaser Mohammed, Al-Worafi. “Drug safety in Egypt”, In: Drug safety in developing countries, Academic Press, 2020.
    10. Erkan, Turan, Erman and Ugur, Bac. “Supply chain performance measurement: a case study about applicability of SCOR model in a manufacturing industry firm”. International journal of business and management studies, Volume 3, Isse 1, 2011.
    11. Ferreira-da-Silva, Renato., Inês Ribeiro-Vaz., Manuela Morato and Jorge Junqueira Polónia. “Guiding axes for drug safety management of pharmacovigilance centres during the COVID-19 era”, International Journal of Clinical Pharmacy, Volume 43, Issue 4, 2021.
    12. Forzley, M. “Combating counterfeit drugs: A concept paper for an international framework convention and related strategies”, World Health Organization, 2004.
    13. Ghanbari, Mohammad Ali; Kourosh Delpasand and Afsaneh Ghanbari, “ Inclusion of Traditional and Complementary Medicine in the United Nations Strategy and the World Health Organization”, Journal of Medical History, Volume 11, Issue 41, 2020. (in Persian)
    14. Glass, Beverley, D. “Counterfeit drugs and medical devices in developing countries”, Research and Reports in Tropical Medicine, 2014.
    15. Gölcük, İlker. “An interval type-2 fuzzy axiomatic design method: A case study for evaluating blockchain deployment projects in supply chain”, Information Sciences,602, 2022.
    16. Hornberger, Julia. “From drug safety to drug security: A contemporary shift in the policing of health”, Medical Anthropology Quarterly,Volume 32, Issue 3, 2018.
    17. Isles, Mike. “What's in a Word? Falsified/Counterfeit/Fake Medicines-The Definitions Debate”, Medicine Access@ Point of Care,1 (1), 2017.
    18. Lebed, Serhii., Alla Nemchenko and Viktoria Nazarkina. “Actuality of the implementation of international practice in proliferation of counterfeit medicines involving Interpol”, Journal of Advanced Pharmacy Education and Research, Volume 10, Issue 2, 2020.
    19. Li, Lisha and Jia, Yin. “Drug safety evaluation in China, Current Allergy and Asthma Reports,Volume 19, 2019.
    20. Mahmoud, Mansour, Adam. “Drug safety in Sudan”, In: Drug Safety in Developing Countries, Academic Press, 2020.
    21. Mammì, Maria., Rita, Citraro., Giovanni, Torcasio., Gennaro, Cusato., Caterina, Palleria and Eugenio Donato, di Paola. “Pharmacovigilance in pharmaceutical companies: An overview”, Journal of Pharmacology and Pharmacotherapeutics,Volume 4, Issue 1_suppl, 2013.
    22. Oumar, A. A., Sangare, M., Fofana, S., Cissoko, Y., Diallo, D., Maiga ,M., et al. “Drug safety in Mali”, In: Drug Safety in Developing Countries, Elsevier, 2020.
    23. Pifferi, Giorgio and Patrizia, Restani. “The safety of pharmaceutical excipients”, Il Farmaco,Volume 58, Issue 8, 2003.
    24. Przyswa, Eric. “Counterfeit medicines and criminal organisations”, IRCAM, 2013.
    25. Sacre, Hala., Aline, Hajj., Randa, Aoun., Souheil, Hallit., Abeer, Zeitoun and Pascale, Salameh. “Drug safety in Lebanon”, In: Drug Safety in Developing Countries, Academic Press, 2020.
    26. Setyadi, Antonius., Erry, Rimawan., Ivan, Kristanto and Puspita, Eka Rohmah. “A proposed conceptual framework of supply chain operations reference (SCOR) model in Indonesian industries: a literature review”, SINERGI, Volume 26, Issue 3, 2022.
    27. Sholy, Lydia., Paul, Gard., Sian, Williams and Angela, MacAdam. “Pharmacist awareness and views towards counterfeit medicine in Lebanon”, International Journal of Pharmacy Practice,Volume 26, Issue 3, 2018.
    28. Sugita, Minoru and Michiko, Miyakawa. “Economic analysis of use of counterfeit drugs: health impairment risk of counterfeit phosphodiesterase type 5 inhibitor taken as an example”, Environmental health and preventive medicine, Volume 15, 2010.
    29. Tinto, H. and Rouamba, T. “Drug safety in Burkina Faso”, In: Drug Safety in Developing Countries, Elsevier, 2020.
    30. Tseng, J. H., Liao, Y. C., Chong B. and Liao, S, W. “Governance on the drug supply chain via gcoin blockchain”, International journal of environmental research and public health, 15 (6), 2018.
    31. UN Assembly General. “International covenant on economic, social and cultural rights”, United Nations, Treaty Series,993 (3), 1966
    32. Varurai, Akbar; Reza Sa’adati and Hamid Hashemi, “Influence of Morality on Criminalization and Decriminalization in the Legal System of Iran”, Jornal of Criminal Law Research, 3 (8), 2014. (in Persian)
    33. White, C. Michael. “Counterfeit drugs: A major issue for vulnerable citizens throughout the world and in the United States”, Journal of the American Pharmacists Association, Volume 61, Issue 1, 2021.
    34. Yakubu R., Isa, A. M., Abubakar, I. J., Oreagba, I. and Awaisu, A. “Drug safety in Nigeria”, In: Drug Safety in Developing Countries, Elsevier; 2020.
    35. Zhang, Li., Jingbo, Yan., Xinmin, Liu., Zuguang, Ye., Xiaohui, Yang., Ronald, Meyboom., Kelvin, Chan., Debbie, Shaw and Pierre, Duez. “Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: current status and future perspective”, Journal of ethnopharmacology,Volume 140, Issue 3, 2012.
    36. Zhu, Peng., Jian, Hu., Yue, Zhang and Xiaotong, Li. “A blockchain based solution for medication anti-counterfeiting and traceability”, Ieee Access, 8, 2020.

    Thesis

    1. Issa, Sara Mahmoud, “The Prospects of Blockchain Technology on the Counterfeit Drugs in Jordan”, Doctoral dissertation, Middle East University, 202

Files

History

  • Receive Date: 08 January 2023
  • Revise Date: 29 August 2023
  • Accept Date: 23 October 2023

Share

How to cite

Statistics